In the end, the secret sauce behind Thursday’s milestone announcement by the Food and Drug Administration to permit 23andMe to market genetic tests for diseases directly to consumers was hard-earned trust.

Now the company will be able to include information on the genetic predisposition for 10 important conditions or diseases — including Parkinson’s and late-onset Alzheimer’s — from a single saliva test that costs $199. The move comes four years after FDA banned 23andMe from selling such data, forcing it back to the drawing board. With exceptions for some tests, such as the genetic marker for breast cancer that often leads to surgical intervention, the agency intends to let the company offer similar tests without premarket review — a landmark for the genetic testing industry as a whole.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy